Community acquired pneumonia

Journal of the Royal College of Physicians of London

Volumn 32, Issue 4, 1998, Pages 328-332

  Finch, Roger ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; MACROLIDE; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; DRUG CHOICE; HEALTH EDUCATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE; MORTALITY; PNEUMONIA; SHORT SURVEY; STREPTOCOCCUS PNEUMONIAE;

COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA;

EID: 0031682957     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs 1998;55:31-45.
2. The British Thoracic Society and the Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987;62:195-220.
3. Macfarlane JT, Miller AC, Roderick Smith WH, Morris AH, et al. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis. Thorax 1984;39:28-33.
4. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991;115:428-36.
5. Karalus NC, Cursons RT, Leng RA, Mahood CB, et al. Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991; 46:413-8.
6. European Respiratory Society. Guidelines for management of adult community-acquired pneumonia (ESOCAP). Eur Respir J 1998;11:986-91.
7. Fine MJ, Smith MA, Carson CA, Mutha SS, et al. Prognosis and outcomes of patients with community-acquired pneumonia -a meta-analysis. JAMA 1996;275: 134-41.
8. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993;49:349-50.
9. Klugman KP. The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. J Antimicrob Chemother 1996;38:133-40.
10. Laurichesse H, Robin F, Gerbaud L, Pochet P, et al. Empirical therapy for non-hospitalized patients with community-acquired pneumonia. Eur Respir J 1998;11:73-8.
11. Gialdroni Grassi G, Brumpt I. Sparfloxacin empirical therapy in community-acquired pneumonia: results of a meta-analysis of two comparative studies. N Engl J Med 1995;49:406-8.
12. O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomised, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997;40:73-81.
13. Salisbury DM, Begg NT (eds). Immunisation against infectious disease. London: HMSO, 1996.